RSS
Home
Business and Finance
Business News
D.C. sniper Muhammad executed for 2002 attacks- John Allen Muhammad, the mastermind behind the sniper attacks that left 10 dead, was executed Tuesday as relatives of the victims watched, reliving the killing spree that terrorized the Washington, D.C., area for three weeks in October 2002.
Blame game erupts over probe of Fort Hood suspect- Finger-pointing erupted between federal agencies Tuesday over Fort Hood shooting suspect Nidal Hasan. Government officials said a Defense Department terrorism investigator looked into Hasan's contacts with a radical imam months ago, but a military official denied prior knowledge of the Army psychiatrist's contacts with any Muslim extremists.
2 dead, 2 wounded in Ore. office park shooting- A woman was killed and two of her co-workers were injured when the woman's estranged husband opened fire Tuesday at a drug-testing laboratory in suburban Portland before turning the gun on himself, police said.
Bill Clinton urges Senate passage of health bill- Former President Bill Clinton urged Senate Democrats on Tuesday to pass health care legislation by year's end, pointedly telling skittish lawmakers that an imperfect bill is preferable to another failure like the one he and the party endured in 1994.
US imam wanted in Yemen over al-Qaida suspicions- A radical American imam who communicated with the Fort Hood shooting suspect and called him a hero was once arrested in Yemen on suspicion of giving religious approval to militants to conduct kidnappings. Yemeni authorities are now hunting for Anwar al-Awlaki to determine whether he has al-Qaida ties.
White House: Obama weighs 4 options in Afghanistan- President Barack Obama is considering four options for realigning U.S. strategy in Afghanistan, his spokesman said Tuesday, while military officials said the choices involve several ways the president could employ additional U.S. forces next year.
- Male factory workers in China who got very high doses of a chemical that's been widely used in hard plastic bottles had high rates of sexual problems, researchers reported Wednesday.
Swift wins 2nd straight BMI award for top song- Taylor Swift started what could be an interesting week with her second straight song of the year award at the BMI Country Awards Tuesday, when Kris Kristofferson was honored as an icon.
Video: For Fall Allergy Season LPGA Player Jill McGill Shares Her Experience Living with Indoor and Outdoor Allergies
"I've lived with indoor and outdoor allergies almost all my life. As a professional golfer, being outside around grass so often and constantly traveling, I know how debilitating the symptoms can be, especially in the fall," says
Challenge Your Course encourages people with indoor and outdoor allergies
to visit their physician to review their current allergy management plan. The
campaign Web site, www.ChallengeYourCourse.com, offers a variety of helpful
information and tools such as an allergy treatment scorecard, tips for
managing indoor and outdoor allergies, and additional background on
"As an allergist, I see how indoor and outdoor allergy symptoms can affect
people every day, especially when they are not properly managed," said
When speaking with their physician, nasal allergy sufferers can learn about available treatment options, including XYZAL(R) (levocetirizine dihydrochloride), a once-daily prescription medication indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of uncomplicated manifestations of chronic idiopathic urticaria (CIU) in adults and children 6 years and older.
Challenge Your Course provides nasal allergy sufferers with the following useful tips, especially helpful during fall allergy season:
-- Keep windows closed to prevent pollen and mold spores from drifting into your home, especially during windy autumn days. Avoid being outside on windy days when pollen counts are higher.
-- Much like mowing the lawn, raking leaves can stir up allergens so avoid this chore if you have severe allergy symptoms.
-- Don't line-dry your clothes outside, as they can collect pollen and mold.
-- When going out to enjoy the fall foliage, avoid the early morning when pollen counts are highest.
-- If you have pets, keep them out of your bedroom to reduce exposure to dander and other allergens they've collected from outside.
Challenge Your Course is supported by UCB and sanofi-aventis, the makers of XYZAL(R) (levocetirizine dihydrochloride).
About XYZAL(R)Indications and Important Safety Information
XYZAL(R) is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) and the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.
The use of XYZAL(R) is contraindicated in: patients with a known hypersensitivity to levocetirizine or any of the ingredients of XYZAL(R) or to cetirizine (observed reactions range from urticaria to anaphylaxis); patients with end-stage renal impairment at less than 10 mL/min creatinine clearance or patients undergoing hemodialysis; and pediatric patients aged 6 to 11 years with impaired renal function.
Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor coordination, such as operating machinery or driving a motor vehicle, after ingestion of XYZAL(R). Concurrent use of XYZAL(R) with alcohol or other central nervous system (CNS) depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.
In clinical trials, the most common adverse reactions in greater than or equal to 2% of adult and adolescent patients (12 years of age and older) taking XYZAL(R) 2.5 mg, XYZAL(R) 5 mg, or placebo were somnolence (5%, 6%, 2%), nasopharyngitis (6%, 4%, 3%), fatigue (1%, 4%, 2%), dry mouth (3%, 2%, 1%), and pharyngitis (2%, 1%, 1%), respectively.
In clinical trials, the most common adverse reactions in greater than or equal to 2% of pediatric patients (6-12 years of age) taking XYZAL(R) 5 mg included pyrexia (4% vs 2% placebo), cough (3% vs greater than or equal to 1% placebo), somnolence (3% vs <1% placebo), and epistaxis (2% vs >1% placebo).
Please visit www.XYZAL.com for full prescribing information.
About Allergic Conditions
Many people suffer from the symptoms associated with common allergic
conditions. The immune system of allergy sufferers over-reacts to something in
the environment, leading to symptoms that affect their respiratory system,
eyes or skin. Experts estimate indoor and outdoor allergies affect as many as
40 million people in
Seasonal allergic rhinitis (SAR), commonly referred to as "hay fever" or "outdoor allergies," is the most common form of allergic rhinitis. By definition, SAR includes allergies to seasonal pollens like grass, trees, and weeds, as well as mold. Perennial Allergic Rhinitis (PAR) is sometimes referred to as "year round" or "indoor allergies" and is characterized by allergic symptoms that last longer than four weeks. Dust mites, animal dander, and mold most commonly trigger PAR. Chronic Idiopathic Urticaria (CIU) is most commonly known as "chronic hives of unknown origin" and is defined as the occurrence of daily, or almost daily, wheals and itching for at least six weeks with no obvious causes.
About UCB
UCB is a global leader in the biopharmaceutical industry dedicated to the
research, development and commercialization of innovative pharmaceutical and
biotechnology products in the fields of central nervous system disorders,
allergy/respiratory diseases, immune and inflammatory disorders and oncology.
Employing approximately 12,000 people in more than 40 countries, UCB achieved
revenue of
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in
About AAFA
The Asthma and Allergy Foundation of America (AAFA), www.aafa.org, is the leading non-profit patient organization fighting asthma and allergic diseases. AAFA provides free consumer information, patient education and funding for research to find cures.
|
|
